Home
Resources
Publications
Liposomal Bupivacaine Versus Bupivacaine Hydrochloride With Lidocaine During Midurethral Sling Placement: A Randomized Controlled Trial

Liposomal Bupivacaine Versus Bupivacaine Hydrochloride With Lidocaine During Midurethral Sling Placement: A Randomized Controlled Trial

Christopher Iwanoff, Charbel Salamon

J Minim Invasive Gynecol. Sep-Oct 2019;26(6):1133-1138.

PMID: 30472302

Abstract:

Study objective:
To study the effects of liposomal bupivacaine (LB) compared with bupivacaine hydrochloride with lidocaine on postoperative day 1 pain scores.
Design:
A randomized controlled trial (Canadian Task Force classification 1).
Setting:
An academic medical center within the department of female pelvic medicine and reconstructive surgery.
Patients:
Fifty-seven patients undergoing midurethral sling placement by a fellowship-trained urogynecologic surgeon and a fellow in female pelvic medicine and reconstructive surgery.
Interventions:
Fifty-seven patients were enrolled to participate in this study. There were 24 patients randomized to receive liposomal bupivacaine and 33 to receive a mixture of bupivacaine and lidocaine during the placement of a retropubic midurethral sling.
Measurements and main results:
Patients were given a diary of pain scales and asked to record their level of pain using the provided visual analog scale scored on a 100-mm Likert scale. Patients recorded their pain 4 hours after hospital discharge and on the night of surgery and their most intense pain each day thereafter for 7 days postoperatively. In addition, patients recorded total opioid and nonsteroidal anti-inflammatory drug consumption daily for 1 week postoperatively. Finally, the quality of recovery was assessed using the Quality of Recovery-15 (QoR-15) questionnaire scores. The median pain score in the experimental group was 20 mm (range, 0-80 mm) versus 30 mm (range, 0-60 mm) in the comparative group (p = .046). The postoperative day 1 QoR-15 scores were significantly lower in the LB group (124 [range, 54-150] vs 144 [range, 68-150], p = .007). There were no significant differences in opioid and nonsteroidal anti-inflammatory drug consumption, the remaining pain scores, or postoperative day 7 QoR-15 scores.
Conclusion:
The results suggest the use of liposomal bupivacaine during retropubic midurethral sling placement does not provide a clinically significant difference in postoperative day 1 pain scores when compared with immediate-acting bupivacaine hydrochloride and lidocaine.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP73360540-B	Bupivacaine hydrochloride		73360-54-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: